Sugi Predict

Sugi Predict / Targets / MAP2K6

MAP2K6

Dual specificity mitogen-activated protein kinase kinase 6 · P52564 · MAP2K6 on Sugi Atlas →

5,233 patent compounds predicted against MAP2K6, 4,359 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL3761722 SCHEMBL3761722 1.00 3/20
SCHEMBL3761756 SCHEMBL3761756 1.00 3/20
SCHEMBL3767636 SCHEMBL3767636 1.00 3/20
SCHEMBL3769201 SCHEMBL3769201 1.00 3/20
SCHEMBL3766711 SCHEMBL3766711 0.78 3/20
SCHEMBL3767397 SCHEMBL3767397 0.77 3/20
SCHEMBL3768925 SCHEMBL3768925 0.75 3/20
SCHEMBL3768919 SCHEMBL3768919 0.74 3/20
SCHEMBL3761689 SCHEMBL3761689 0.73 3/20
SCHEMBL3756415 SCHEMBL3756415 0.73 3/20
SCHEMBL3767552 SCHEMBL3767552 0.71 3/20
SCHEMBL3756906 SCHEMBL3756906 0.70 3/20
SCHEMBL3760419 SCHEMBL3760419 0.70 3/20
Trifluoroacetic Acid Trifluoroacetic Acid (SCHEMBL3756875) 0.69 3/20
SCHEMBL3758760 SCHEMBL3758760 0.68 3/20
SCHEMBL3762687 SCHEMBL3762687 0.68 3/20
SCHEMBL3756630 SCHEMBL3756630 0.67 3/20
SCHEMBL3761735 SCHEMBL3761735 0.67 3/20
SCHEMBL3761908 SCHEMBL3761908 0.67 3/20
SCHEMBL3767631 SCHEMBL3767631 0.66 3/20

Clinical trials — most relevant to MAP2K6 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma PHASE4UNKNOWN
Overcoming Endocrine Resistance in Metastatic Breast Cancer PHASE3UNKNOWN
To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib. PHASE2UNKNOWN
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma PHASE1/PHASE2COMPLETED
Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant PHASE2RECRUITING
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma PHASE1/PHASE2COMPLETED
Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma PHASE2UNKNOWN
MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas PHASE2ACTIVE_NOT_RECRUITING
Neoadjuvant GW572016 to Treat Breast Cancer PHASE2COMPLETED
HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies PHASE1/PHASE2RECRUITING
ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy PHASE2COMPLETED
Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma PHASE2ACTIVE_NOT_RECRUITING
Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer PHASE2COMPLETED
MEK162 for Patients With RAS/RAF/MEK Activated Tumors PHASE2COMPLETED
Clinical Study on the Treatment of Type I Neurofibromatosis With Smeitinib Hydrosulfate Capsule PHASE2NOT_YET_RECRUITING
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101 PHASE1WITHDRAWN
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212 PHASE1COMPLETED
Phase I Study of Gemcitabine, Sorafenib and Radiotherapy in Patients With Unresectable Pancreatic Cancer PHASE1COMPLETED
Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2 PHASE1COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors PHASE1NOT_YET_RECRUITING
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma PHASE1COMPLETED
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
Natural History, Pathogenesis and Outcome of Melorheostosis A Rare Osteosclerotic Disease nanRECRUITING
Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo nanUNKNOWN
Identification of Novel Targetable Kinases in SR-a GvHD nanCOMPLETED
BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients nanCOMPLETED
A Multi-omics Study of BRAF V600E Mutant Colorectal Cancer nanNOT_YET_RECRUITING
Veristrat as Predictor of Benefit of First Line Non Small Cell Lung Cancer (NSCLC) Patients From Standard Chemotherapy nanUNKNOWN
Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment nanACTIVE_NOT_RECRUITING
Pertuzumab in First Line Treatment of HER2-positive Metastatic Breast Cancer Patients nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a MAP2K6 binder may also engage these)

ProteinNameSimilarity
Q5E9X2 — 1.000 Q5E9X2 →
P70236 — 1.000 P70236 →
Q9DGE0 — 1.000 Q9DGE0 →
O09110 — 0.997 O09110 →
MAP2K3 Dual specificity mitogen-activated protein kinase kinase 3 0.997 landscape →
P47809 — 0.986 P47809 →
G5EDF7 — 0.986 G5EDF7 →
MAP2K4 Dual specificity mitogen-activated protein kinase kinase 4 0.983 landscape →
Q9ES74 — 0.980 Q9ES74 →
G5EFM9 — 0.980 G5EFM9 →
Q91447 — 0.978 Q91447 →
Q90321 — 0.978 Q90321 →
Q63980 — 0.977 Q63980 →
MAP2K1 Dual specificity mitogen-activated protein kinase kinase 1 0.977 landscape →
Q05116 — 0.977 Q05116 →
Q90891 — 0.976 Q90891 →
P29678 — 0.976 P29678 →
NEK7 Serine/threonine-protein kinase Nek7 0.976 landscape →
P31938 — 0.976 P31938 →
Q9XT09 — 0.975 Q9XT09 →
P10506 — 0.975 P10506 →
Q1HG70 — 0.974 Q1HG70 →
P59895 — 0.974 P59895 →
Q01986 — 0.974 Q01986 →
Q5QN75 — 0.974 Q5QN75 →
MAP2K2 Dual specificity mitogen-activated protein kinase kinase 2 0.974 landscape →
D3ZBE5 — 0.973 D3ZBE5 →
P36506 — 0.972 P36506 →
A2BD05 — 0.972 A2BD05 →
NEK6 Serine/threonine-protein kinase Nek6 0.972 landscape →